Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

cation in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "10
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
(Date:8/30/2014)... Calif. (PRWEB) August 30, 2014 Insomnia causes ... helps listeners understand how they unknowingly developed insomnia and the ... restful nights during. Tune in to the show at ... The show airs live on August 30, and will be ... information on programming, go to DrCarolFrancisTalkRadio.com. , "Insomnia ...
(Date:8/30/2014)... Randy Dotinga HealthDay ... About one in five patients operated on for broken bones ... surgery, a new study finds. Less-educated patients and ... more likely to be "doctor shoppers," said study lead author ... Ky. Overall, he said, the study suggests that doctors aren,t ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Hastings and ... injury attorneys located throughout Arizona is pleased to report ... is one specific example among many cases where Hastings ... are able to retain a greater portion of their ... case that providing a positive solution for Arizona car ...
(Date:8/30/2014)... Administration of colchicine, a plant-based medication commonly used ... showed mixed results in reducing potential complications from ... the risk of gastrointestinal adverse effects, according to ... study is being released early online to coincide ... Cardiology Congress. , Common complications after cardiac surgery ...
(Date:8/30/2014)... 2014 "My niece developed a nighttime ... any moment, her fever might get worse," said an ... well aware of how she was doing, I developed ... to continuously monitor a child's temperature. The unit instantly ... ensures that prompt medical care can be given, which ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Medication shows mixed results in reducing complications from cardiac surgery 2
... closely watching the developments in a little-known southwestern Ontario ... vaccine-related exposure among its members. // ,This ... the United States. Health officials are not disclosing the ... thought to be in close vicinity of the Middlesex ...
... is on track to roll-out a nationwide screening programme ... infertility in both sexes//. ,So far nearly 80,000 ... difficult to detect but is easy to cure, following ... Programme (NCSP). ,There has been a heightened concern ...
... is a very famous saying which refers to an attitude ... achieve it and so feign that we are not concerned ... Everybody knows it's good; yet many people still avoid it, ... above statement researchers at the University of Illinois at Urbana-Champaign ...
... As per a Goldman Sachs report, bird flu may reduce ... is easily transmitted among humans, possibly by more than 1-million ... barrels a day, according to data issued by the US ... true global pandemic, the economic implications would be profound, potentially ...
... The FDA has sent shock waves in the industry ... Nov. 8 from the U.S. Food and Drug Administration ... for qualified health claims for lycopene, tomatoes, and tomatoes-based ... lycopene (tomatoes, tomato-based foods containing lycopene) may reduce the ...
... found that less volume of white matter in the frontal lobe ... of decline in brain activity//. The researchers have found that the ... related but due to not using the white matter (frontal lobe) ... the left side of the brain which contains the Grey matter ...
Cached Medicine News:Health News:UK Govt Says On Course For National Chlamydia Screening 2Health News:Important parameters of life: Longevity and quality: both improved by exercise 2Health News:Important parameters of life: Longevity and quality: both improved by exercise 3Health News:Bird Flu Likely To Reduce World Energy Demand 2
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: